Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

US President Donald Trump has signed an executive order telling drugmakers to cut prices to 'most favoured nation' pricing.

The European Commission (EC) has granted orphan drug designation to Biodexa Pharmaceuticals’ oral tablet formulation of ...

The executive order aims to cut US prescription drug costs by linking them to the lowest prices paid internationally.